Key facts
- This page summarizes Brian Corvese's Form 4 filing for Protagenic Therapeutics, Inc.\new (PTIX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Mar 2024, 21:29.
Brian Corvese - 25 Mar 2024 Form 4 Insider Report for Protagenic Therapeutics, Inc.\new (PTIX)
- Reporting relationship
- Director
- Issuer ticker
- PTIX
- Reported as of
- 25 Mar 2024
- Net transaction value
- +$76,125
- SEC form
- 4
- Accepted by SEC
- 29 Mar 2024, 21:29:10 UTC
- Prior SEC filing
- 05 Mar 2024
- Next SEC filing
- 05 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christine Klaskin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian Corvese filed Form 4 for Protagenic Therapeutics, Inc.\new (PTIX) on 29 Mar 2024.
Change
- Previous filing in this sequence was filed on 05 Mar 2024.
- Current net transaction value: +$76,125.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PTIX
transaction
Derivative
PTIX Common stock Options
Award
- Transaction value
- $76,125
- Shares
- +43,750
- Change %
- Price
- $1.74
- Shares after
- 43,750
- Date
- 25 Mar 2024
- Ownership
- Direct
- Underlying class
- PTIX Common Stock, Par Value $0.0001
- Underlying amount
- 43,750
- Exercise price
- $1.74
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
The options vest monthly over 24 months, commencing upon the date of grant, with full acceleration upon a change of control.